Drug Marketers Are Finding Creative Applications For SGLT-2 Drugs Ignoring The Risk of Fournier's Gangrene

Diabetes Drug Infection Lawsuit News

Drug marketers highlight any benefit they can find to incentivize doctors to prescribe sodium-glucose blocker drugs to their diabetic patients but ignore the link to Fournier's Gangrene, a form of genital necrotizing fasciitis by the FDA

Thursday, October 24, 2019 - Type 2 diabetic patients that do not wish to physically inject themselves with insulin several times per day may opt to take a sodium-glucose blocker drug (SGLT-2) to regulate their blood sugar level. SGLT-2 drugs work by preventing the SGLT-2 protein from transferring glucose filtered in the kidneys back into the bloodstream and instead redirect it out of the body through the urine. SGLT-2 drugs have the added benefits of helping to lower blood pressure and to aid in weight loss. The drugs are also being touted by drug companies for preventing kidney failure, lowering blood pressure, and a whole host of miraculous achievements. Drug marketing websites are seizing on studies and reports to use a tool to sell more SGLT2 drugs. National diabetes drug infection attorneys are available to answer your questions about Fournier necrotizing fasciitis. Fournier gangrene lawsuits handled by top national attorneys with a distinguished record having won major settlements against multinational pharmaceutical conglomerates on behalf of American families harmed by dangerous drugs and defective medical devices.

While most studies are inconclusive and only suggestive, one published in The Lancet, Diabetes & Endocrinology reported that sodium-glucose blocker drugs can lower the instances of kidney failure in diabetic patients. "SGLT2 inhibitors reduced the risk of dialysis, transplantation, or death due to kidney disease in individuals with type 2 diabetes and protected against acute kidney injury. These data provide substantive evidence supporting the use of SGLT2 inhibitors to prevent major kidney outcomes in people with type 2 diabetes."

Invokana is the leading SGLT2 blocker drug and boasts on the top of their home page of the ancillary benefits of taking the diabetic drug. "Now Approved-The only type 2 diabetes medicine proven to lower the risks of end-stage kidney disease (ESKD), worsening of kidney function, cardiovascular death, hospitalization for heart failure in adults with type 2 diabetes and diabetic kidney disease." The home page goes on to make patients aware of how critical diabetic kidney disease can be and that "Nearly 1 in 3 adults with type 2 diabetes has diabetic kidney."

Such impressive benefits are not without risks, however, and there have been some SGLT2 diabetic patients that have developed Fournier's Gangrene, a rare but often deadly form of the flesh-eating disease that consumes one's genitals. SGLT-2 blocker drugs that the FDA has linked with Fournier's Gangrene include canagliflozin (Invokana), canagliflozin/metformin (Invokamet), and dapagliflozin (Farxiga). Treatments for Fournier's Gangrene usually require genital amputation or mutilation for men. There have been 55 reported cases of Fournier's Gangrene and that number could be much greater because so few doctors and even fewer diabetic patients have ever heard of the condition where the connection to diabetic drugs is usually overlooked. If you have developed genital pain and swelling you should immediately see a doctor but continue to take your diabetes medication until your doctor advises otherwise.

More Recent Diabetes Drug Infection Lawsuit News:

Lawyers for Fournier's Gangrene

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.